Medical treatment for botulism.

Area of Science:

• Neurology
• Infectious Diseases
• Pharmacology

Background:

• Botulism is a severe paralytic illness caused by Clostridium botulinum neurotoxins.
• Current management relies heavily on supportive care, with limited evidence for specific medical treatments.
• This review is an update of previous findings on botulism treatments.

Purpose of the Study:

• To evaluate the efficacy of medical treatments for botulism, focusing on mortality and duration of hospitalization.
• To assess the impact of treatments on mechanical ventilation and feeding requirements.
• To determine the risk of adverse events associated with botulism therapies.

Main Methods:

• Searched major databases (Cochrane, MEDLINE, Embase) and clinical trial registers up to February 2019.
• Included randomized controlled trials (RCTs) and quasi-RCTs for all major botulism types.
• Evaluated treatments such as antitoxins, immune globulins, plasma exchange, and other drugs.

Main Results:

• A single RCT on infant botulism met criteria, evaluating human-derived botulinum immune globulin intravenous (BIG-IV).
• BIG-IV significantly reduced hospitalization duration (3.1 weeks shorter) and tube/parenteral feeding duration (6.4 weeks shorter) with moderate certainty evidence.
• BIG-IV possibly reduced mechanical ventilation duration (2.6 weeks shorter) with low certainty evidence; no significant difference in adverse events was found.

Conclusions:

• Low- to moderate-certainty evidence supports BIG-IV for infant intestinal botulism.
• BIG-IV likely shortens hospitalization and treatment durations, with no increased risk of adverse events.
• No evidence was found for other medical treatments like antitoxins.